Keywords: sanofi-synthelabo, sells, arixtra, fraxiparine, gsk, 453m, euros
Sanofi-Synthelabo sells Arixtra and Fraxiparine to GSK for 453M euros
Article | 19 April 2004
GlaxoSmithKline said on April 13 that it has signed an agreement to acquire, on a worldwide basis, Sanofi-Synthelabo's injectable antithrombotic agents ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
